

Institut national de la santé et de la recherche médicale





# Study of interactions between dsDNA and anti-dsDNA antibodies in Autoimmune Hepatitis and Systemic Lupus Erythematosus using Surface Plasmon Resonance Imaging-based strategy

• E. Ballot

Praticien Hospitalier, Hôpital Saint-Antoine, Paris

•J.C. Duclos-Vallée Professeur des Universités, Hôpital Paul Brousse, Villejuif

• Eleonora De Martin Assistante hospitalo-universitaire , Hôpital Paul Brousse, Villejuif • Malcolm Buckle Directeur de Recherche, ENS Cachan

• Hervé Leh Ingénieur de recherche, ENS Cachan

# Background

• Anti-double strand-DNA (ds-DNA) antibodies are specific for systemic lupus erythematosus (SLE), but can also be detected in 30% of type 1 autoimmune hepatitis (AIH) patients.

Muratori, Am J Gastroenterol 2009

• Some AIH sera are ANA negative by IIF but positive for antidsDNA by Farr test.

Saint-Antoine Immunology laboratory Unpublished results

• Antibodies avidity varies with different antigenic dsDNAs, as demonstrated by kinetics binding variations.

Buhl, Biosens and Bioel 2009

## **SPR-based strategy**

Surface Plasmon Resonance (SPR) is a real-time, label-free, optical detection method for studying the interaction of soluble analyte with immobilized ligand

### Résonance plasmonique de surface (SPR) (1)



- A l'interface de 2 matériaux ayant des indices de réfraction différents
- Réflexion totale interne : au-dessus d'un angle particulier, quand n1 > n2.
- En même temps, une onde électromagnétique évanescente se propage en s'éloignant de l'interface.

## Résonance plasmonique de surface (SPR) (2)



- Mince film conducteur à l'interface
- L'interaction résonnante entre l'onde électromagnétique évanescente et les électrons libres du métal provoque une onde de densité d'électron appelé plasmon de surface et qui présente un caractère évanescent

## Résonance plasmonique de surface (SPR) (3)



Composante longitudinale du vecteur d'onde du plasmon,

- Le champs évanescent créé par en condition de réflexion totale (par le prisme) permet de coupler un plasmon de surface.
- Une portion de la lumière incidente se complexe au plasmon.
- De l'énergie est absorbée par la résonance, l'intensité de la lumière réfléchie chute à l'angle de la SPR.

$$K_{sp} = \frac{\omega}{c} \sqrt{\frac{\mathcal{E}m.\mathcal{E}d}{\mathcal{E}m + \mathcal{E}d}} \quad \text{avec } \varepsilon = n^2$$

### Résonance plasmonique de surface (SPR) (4)



#### Résonance plasmonique de surface (SPR) (5)

#### Imagerie par résonance plasmonique de surface (SPRi)



#### Imagerie par résonance plasmonique de surface (SPRi)



#### SPRi-based strategy Sensorgram analysis

<u>d[RL]</u>

dt



#### Aim

To monitor the interactions between dsDNA and antidsDNA antibodies in autoimmune hepatitis and systemic lupus erythematosus, using surface plasmon resonance imagery (SPRi) focusing on Ag-Ab complex stability and dissociation constant rate  $k_{off}$  calculation.

#### **Patients sera**

#### SERA /IFI on Hep-2 cells, anti-dsDNA by Farr test, diagnosis confirmed

AIH ,	AIH,	SLE,	Negative
ANA IIF +/dsDNA +	ANA IIF -/dsDNA +	ANA IFI +/dsDNA +	Control
n = 9	n = 5	n = 7	n = 7

## IgGs and IgMs purification



**'Protein G HP SpinTrap' kit** (GE Healthcare)



'HiTrap IgM Purification HP' kit (GE Healthcare)

## dsDNAs - Antigens

DNA	Вр	Modification	Methylation
o500	500	5'-thiol C3 spacer	No
o500c	500	5'-thiol C3 spacer	CpG (5Me-C)
o500g	500	5'-thiol C3 spacer	CpG (5Me-C)
o250	250	5'-thiol C3 spacer	No
o2/10	27	5'-thiol	No
o2/10c	27	5'-thiol	CpG (5Me-C)
o2/10	27	5'-thiol	EcoRI (6Me-A)
hp	22	5'-thiol and Hairpin with a 3 bases loop	No
THF	22	5'-thiol and Tetrahydrofurane (abasic site) in position 10	No
DL10	40	5'-thiol and ethenoA in position 10	No

Characteristics of oligonucleotides used as antigen (bp, bases pairs). DNAs were spotted at  $1\mu M$ 

## **Chip surface design**



• Biochip is surmounted with a sparse self-assembled monolayer of ethylen glycol (SAM).

• The dsDNA with a thiol modification in 5' end is adsorbed between the SAM.

## **Results: AIH Serum – anti-IgG**



Sensograms AIH patient (800-fold dilution) and after anti-IgGs injection



Differential images of chip surface at AIH sera injection (left) and anti-IgG injection (right)

## **Results: SLE Serum – anti-IgG**



Sensograms SLE patient (800-fold dilution) and after anti-IgGs injection



Differential images of chip surface at SLE sera injection (left) and anti-IgGs injection (right)

## **Results: control Serum– anti-IgG**



Sensograms control patient (800-fold dilution) and after anti-IgGs injection



Differential images of chip surface at control serum injection (left) and anti-IgGs injection (right)

## **Results: AIH Serum– anti-IgM**



Sensograms AIH patient (800-fold dilution) and after anti-IgMs injection



Differential images of chip surface at control serum injection (left) and anti-IgMs injection (right)

# **Purified IgGs**







Representative SPRi sensograms obtained: **a.** AIH IgGs; **b.** SLE (5) IgGs; **c.** control IgGs Interacting with immobilized DNAs. SLE except number 5 have a similar reactivity than controls.

#### **Reflectivity SLE purified IgMs**



Representative surface plasmon resonance sensograms obtained after IgMs of SLE patient number 5, interacting with immobilized dsDNA

#### Reflectivity AIH purified IgGs according to oligonucleotides



The maximal reflectivity for each DNA is divided by the signal of o250 DNA

#### K<sub>off</sub> AIH purified IgGs and dsDNAs

	HAI	SLE								
	1	4	9	10	11	17	18	19	20	5
250b	1.99	1.18	1.98	1.99	2.19	1.01	1.32	2.00	1.22	1.73
	E-03									
o500	ND	7.58	0.95	ND	2.51	4.92	4.92	ND	1.88	2.38
		E-03	E-03		E-03	E-03	E-03		E-03	E-03
o2/10c	1.19	0.90	3.10	3.02	1.64	0.86	2.11	2.26	1.79	1.99
	E-03									
o2/10e	0.67	1.04	6.67	2.65	1.76	1.09	1.79	2.77	0.73	1.96
	E-03									
o2/10	ND	0.54	1.52	3.31	1.58	0.89	1.08	1.88	1.73	1.52
		E-03	E-03	E-02	E-03	E-03	E-03	E-03	E-03	E-03

Mean  $k_{off}$  of interactions between purified IgGs from AIH patients and dsDNA on the chip surface. Mean  $k_{off}$  are expressed in sec-. ND: not determined, because of too low intensity

#### Conclusion

• SPRi strategy can detect variation among autoantibodies binding to dsDNA in different diseases

• Serum components from AIH, SLE and control sera bind dsDNAs, mostly IgGs for AIH patients

• AIH purified IgGs from sera bind dsDNAs compared to SLE and control IgGs

• SLE patients the immunocomplex formation might require a third partner that has to be identified, or a specific dsDNA structure

• IgMs tested do not bind tested dsDNAs

• Mean dissociation off rate for IgGs (K<sub>off</sub>) were comparable among AIH patients

#### **Future perspective**

To study the third partner

- 1. MALDI-TOF spectrometry : after SPRi study the chip surface can be transferred into a spectrometer. Mass data analysis can help in the elucidation of the different compound between AIH and SLE.
- 2D electrophoresis + mass spectrometry : treatment of the chip surface with TCEP, 2D electrophoresis, treatment with trypsine and mass spectrometry.

to study a specificity conformation

1. SPRi with inversion of analyte and ligand : purified IgGs can spotted over the chip surface and dsDNAs injected in the flow chamber. dsDNAs with different conformation can be injected.